REDX PHARMA PLC
("Redx" or the "Company")
Holdings in Company
Alderley Park, UK, 9 November 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer, announces the following changes to its significant shareholders (being shareholders holding 3% or more of the Company's ordinary shares) pursuant to AIM Rule 17, following admission of the Subscription Shares to trading on AIM (as announced on 7 November 2023) and as detailed further in the circular to shareholders dated 18 October 2023.
| Shareholder | Number of ordinary shares | Percentage of issued share capital |
| Funds managed by Redmile Group LLC | 276,890,319 | 71.18 |
| Sofinnova Crossover I SLP | 51,948,307 | 13.35 |
| Polar Capital LLP | 24,321,504 | 6.25 |
| Invus Public Equities L.P. | 15,203,815 | 3.91 |
| For further information, please contact: |
|
|
|
|
| Redx Pharma plc Caitlin Pearson, Head of Communications ir@redxpharma.com UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 |
| US Office Peter Collum, Chief Financial Officer | |
| |
|
| SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
| Matt Davis/ Adam Dawes | |
|
WG Partners LLP (Joint Broker) |
T: +44 (0)203 705 9330 |
| Claes Spång/ Satheesh Nadarajah/ David Wilson | |
|
Panmure Gordon (UK) Limited (Joint Broker) |
T: +44 (0)207 886 2500 |
| Rupert Dearden/ Freddy Crossley/ Emma Earl |
|
| FTI Consulting | T: +44 (0)203 727 1000 |
| Simon Conway/ Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application during the fourth quarter of 2023. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development. In October 2023, Redx nominated its next development candidate, RXC009 a highly potent and selective DDR1 inhibitor for the treatment of chronic kidney disease and associated fibrosis.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.